Eli Lilly’s research division has sparked considerable fervor for its Phase II topline reading on next-generation Alzheimer’s drug donanemab. But after spelling out the data over the weekend, you can expect some experts in the field to take a much more measured stance on the chances of approval by the regulator.
Lilly announced a statistically significant result for the new primary endpoint: change from baseline in the 76-week score on the integrated Alzheimer’s disease scale, or iADRS, which is a combined score on cognition and function that indicated that the N3pG beta-amyloid drug could slow the deterioration of patients in the early stages, eagerly digested in an area of R&D with millions of patients currently having nothing to address the memory-wasting ailment.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.